Publications by Jan Terje Andersen

110 publications found

Publications 2025

  1. Anthi AK, Kolderup A, Vaage EB, Bern M, Benjakul S, Tjärnhage E, Ruso-Julve F, Jensen KR, Lode HE, Vaysburd M, Nilsen J, Herigstad ML, Sakya SA, Tietze L, Pilati D, Nyquist-Andersen M, Dürkoop M, Gjølberg TT, Peng L, Foss S, Moe MC, Low BE, Wiles MV, Nemazee D, Jahnsen FL et al. (2025)
    An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models
    Nat Commun, 16 (1), 3999
    DOI 10.1038/s41467-025-59353-6, PubMed 40312392
  2. Gelli HP, Vazquez-Uribe R, Buckley ST, Andersen JT, Alexander Sommer MO (2025)
    Advanced microbiome therapeutics for oral delivery of peptides and proteins: Advances, challenges, and opportunities
    Adv Drug Deliv Rev, 222, 115603
    DOI 10.1016/j.addr.2025.115603, PubMed 40349728
  3. Gjølberg TT, Mester S, Calamera G, Telstad JS, Sandlie I, Andersen JT (2025)
    Targeting the Neonatal Fc Receptor in Autoimmune Diseases: Pipeline and Progress
    BioDrugs, 39 (3), 373-409
    DOI 10.1007/s40259-025-00708-2, PubMed 40156757
  4. Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT (2025)
    Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life
    PNAS Nexus, 4 (2), pgaf042
    DOI 10.1093/pnasnexus/pgaf042, PubMed 40041621
  5. Nilsen J, Aaen KH, Benjakul S, Ruso-Julve F, Greiner TU, Bejan D, Stensland M, Singh S, Schlothauer T, Sandlie I, Andersen JT (2025)
    Enhanced plasma half-life and efficacy of engineered human albumin-fused GLP-1 despite enzymatic cleavage of its C-terminal end
    Commun Biol, 8 (1), 810
    DOI 10.1038/s42003-025-08249-8, PubMed 40419755
  6. Pilati D, Agyei EK, Elkhashab M, Fuchs E, Nielsen IH, Bjerg TW, Anthi AK, Jiménez-Reinoso A, Iversen MB, Pohl L, Narita R, Frago S, Jakobsen MR, Andersen JT, Degn SE, Paludan SR, Alvarez-Vallina L, Howard KA (2025)
    Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction
    J Biol Chem, 301 (6), 108508 (in press)
    DOI 10.1016/j.jbc.2025.108508, PubMed 40222546
  7. Trabjerg E, Nilsen J, Tollefsrud Gjølberg T, Andersen JT, Leitner A, Rand KD (2025)
    Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation
    Commun Biol, 8 (1), 922
    DOI 10.1038/s42003-025-08252-z, PubMed 40506471

Publications 2024

  1. Bashour H, Smorodina E, Pariset M, Zhong J, Akbar R, Chernigovskaya M, Lê Quý K, Snapkow I, Rawat P, Krawczyk K, Sandve GK, Gutierrez-Marcos J, Gutierrez DN, Andersen JT, Greiff V (2024)
    Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
    Commun Biol, 7 (1), 922
    DOI 10.1038/s42003-024-06561-3, PubMed 39085379
  2. Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gjølberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT (2024)
    Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
    Nat Commun, 15 (1), 2007
    DOI 10.1038/s41467-024-46321-9, PubMed 38453922
  3. Lustig M, Hahn C, Leangen Herigstad M, Andersen JT, Leusen JHW, Burger R, Valerius T (2024)
    Sialylation inhibition improves macrophage mediated tumor cell phagocytosis of breast cancer cells triggered by therapeutic antibodies of different isotypes
    Front Oncol, 14, 1488668
    DOI 10.3389/fonc.2024.1488668, PubMed 39659795
  4. Reusch J, Andersen JT, Rant U, Schlothauer T (2024)
    Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn
    MAbs, 16 (1), 2361585
    DOI 10.1080/19420862.2024.2361585, PubMed 38849969
  5. Tulika T, Ruso-Julve F, Ahmadi S, Ljungars A, Rivera-de-Torre E, Wade J, Fernández-Quintero ML, Jenkins TP, Belfakir SB, Ross GMS, Boyens-Thiele L, Buell AK, Sakya SA, Sørensen CV, Bohn MF, Ledsgaard L, Voldborg BG, Francavilla C, Schlothauer T, Lomonte B, Andersen JT, Laustsen AH (2024)
    Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling
    Structure, 32 (9), 1404-1418.e7
    DOI 10.1016/j.str.2024.07.014, PubMed 39146931

Publications 2023

  1. Benjakul S, Anthi AK, Kolderup A, Vaysburd M, Lode HE, Mallery D, Fossum E, Vikse EL, Albecka A, Ianevski A, Kainov D, Karlsen KF, Sakya SA, Nyquist-Andersen M, Gjølberg TT, Moe MC, Bjørås M, Sandlie I, James LC, Andersen JT (2023)
    A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery
    PNAS Nexus, 2 (12), pgad403
    DOI 10.1093/pnasnexus/pgad403, PubMed 38077689
  2. Fernández-Quintero ML, Ljungars A, Waibl F, Greiff V, Andersen JT, Gjølberg TT, Jenkins TP, Voldborg BG, Grav LM, Kumar S, Georges G, Kettenberger H, Liedl KR, Tessier PM, McCafferty J, Laustsen AH (2023)
    Assessing developability early in the discovery process for novel biologics
    MAbs, 15 (1), 2171248
    DOI 10.1080/19420862.2023.2171248, PubMed 36823021
  3. Gjølberg TT, Wik JA, Johannessen H, Krüger S, Bassi N, Christopoulos PF, Bern M, Foss S, Petrovski G, Moe MC, Haraldsen G, Fosse JH, Skålhegg BS, Andersen JT, Sundlisæter E (2023)
    Antibody blockade of Jagged1 attenuates choroidal neovascularization
    Nat Commun, 14 (1), 3109
    DOI 10.1038/s41467-023-38563-w, PubMed 37253747
  4. Jørstad ØK, Foss S, Gjølberg TT, Mester S, Nyquist-Andersen M, Sivertsen MS, Fossum D, Gleditsch E, Moe MC, Andersen JT (2023)
    Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties
    Int J Retina Vitreous, 9 (1), 65
    DOI 10.1186/s40942-023-00507-3, PubMed 37936232
  5. Lustig M, Chan C, Jansen JHM, Bräutigam M, Kölling MA, Gehlert CL, Baumann N, Mester S, Foss S, Andersen JT, Bastian L, Sondermann P, Peipp M, Burger R, Leusen JHW, Valerius T (2023)
    Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells
    Front Immunol, 14, 1178817
    DOI 10.3389/fimmu.2023.1178817, PubMed 37346044
  6. Mukadam AS, Miller LVC, Smith AE, Vaysburd M, Sakya SA, Sanford S, Keeling S, Tuck BJ, Katsinelos T, Green C, Skov L, Kaalund SS, Foss S, Mayes K, O'Connell K, Wing M, Knox C, Banbury J, Avezov E, Rowe JB, Goedert M, Andersen JT, James LC, McEwan WA (2023)
    Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models
    Science, 379 (6639), 1336-1341
    DOI 10.1126/science.abn1366, PubMed 36996217
  7. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2023)
    Author Correction: Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
    NPJ Vaccines, 8 (1), 4
    DOI 10.1038/s41541-023-00600-6, PubMed 36697432
  8. Tulika T, Pedersen RW, Rimbault C, Ahmadi S, Rivera-de-Torre E, Fernández-Quintero ML, Loeffler JR, Bohn MF, Ljungars A, Ledsgaard L, Voldborg BG, Ruso-Julve F, Andersen JT, Laustsen AH (2023)
    Phage display assisted discovery of a pH-dependent anti-α-cobratoxin antibody from a natural variable domain library
    Protein Sci, 32 (12), e4821
    DOI 10.1002/pro.4821, PubMed 37897425

Publications 2022

  1. Akbar R, Bashour H, Rawat P, Robert PA, Smorodina E, Cotet TS, Flem-Karlsen K, Frank R, Mehta BB, Vu MH, Zengin T, Gutierrez-Marcos J, Lund-Johansen F, Andersen JT, Greiff V (2022)
    Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies
    MAbs, 14 (1), 2008790
    DOI 10.1080/19420862.2021.2008790, PubMed 35293269
  2. Akbar R, Robert PA, Weber CR, Widrich M, Frank R, Pavlović M, Scheffer L, Chernigovskaya M, Snapkov I, Slabodkin A, Mehta BB, Miho E, Lund-Johansen F, Andersen JT, Hochreiter S, Hobæk Haff I, Klambauer G, Sandve GK, Greiff V (2022)
    In silico proof of principle of machine learning-based antibody design at unconstrained scale
    MAbs, 14 (1), 2031482
    DOI 10.1080/19420862.2022.2031482, PubMed 35377271
  3. Foss S, Jonsson A, Bottermann M, Watkinson R, Lode HE, McAdam MB, Michaelsen TE, Sandlie I, James LC, Andersen JT (2022)
    Potent TRIM21 and complement-dependent intracellular antiviral immunity requires the IgG3 hinge
    Sci Immunol, 7 (70), eabj1640
    DOI 10.1126/sciimmunol.abj1640, PubMed 35486676
  4. Gjølberg TT, Frick R, Mester S, Foss S, Grevys A, Høydahl LS, Jørstad ØK, Schlothauer T, Sandlie I, Moe MC, Andersen JT (2022)
    Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life
    Commun Biol, 5 (1), 832
    DOI 10.1038/s42003-022-03787-x, PubMed 35982144
  5. Gjølberg TT, Lode HE, Melo GB, Mester S, Probst C, Sivertsen MS, Jørstad ØK, Andersen JT, Moe MC (2022)
    A Silicone Oil-Free Syringe Tailored for Intravitreal Injection of Biologics
    Front Ophthalmol (Lausanne), 2, 882013
    DOI 10.3389/fopht.2022.882013, PubMed 38983507
  6. Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT (2022)
    Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
    iScience, 25 (2), 103746
    DOI 10.1016/j.isci.2022.103746, PubMed 35118359
  7. Mørtberg TV, Zhi H, Vidarsson G, Foss S, Lissenberg-Thunnissen S, Wuhrer M, Michaelsen TE, Skogen B, Stuge TB, Andersen JT, Newman PJ, Ahlen MT (2022)
    Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody
    Immunohorizons, 6 (1), 90-103
    DOI 10.4049/immunohorizons.2100097, PubMed 35074850
  8. Sand KMK, Gruber MM, Sandlie I, Mathiesen L, Andersen JT, Wadsack C (2022)
    Contribution of the ex vivo placental perfusion model in understanding transplacental immunoglobulin G transfer
    Placenta, 127, 77-87
    DOI 10.1016/j.placenta.2022.07.019, PubMed 35981406
  9. Søraas A, Grødeland G, Granerud BK, Ueland T, Lind A, Fevang B, Murphy SL, Huse C, Nygaard AB, Steffensen AK, Al-Baldawi H, Holberg-Petersen M, Andresen LL, Ågnes C, Ranheim T, Schanke Y, Istre M, Dahl JA, Chopra A, Dudman S, Kaarbø M, Andersen JT, Vaage EB, Tran TT, Vaage JT et al. (2022)
    Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity
    Front Immunol, 13, 964525
    DOI 10.3389/fimmu.2022.964525, PubMed 36159859
  10. Tran TT, Vaage EB, Mehta A, Chopra A, Tietze L, Kolderup A, Anthi A, König M, Nygaard G, Lind A, Müller F, Nissen-Meyer LS, Magnus P, Trogstad L, Mjaaland S, Søraas A, Midtvedt K, Åsberg A, Barratt-Due A, Medhus AW, Høivik ML, Lundin K, Karlsen RF, Dahle R, Danielsson K et al. (2022)
    Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
    NPJ Vaccines, 7 (1), 174
    DOI 10.1038/s41541-022-00586-7, PubMed 36585405
  11. Wade J, Rimbault C, Ali H, Ledsgaard L, Rivera-de-Torre E, Abou Hachem M, Boddum K, Mirza N, Bohn MF, Sakya SA, Ruso-Julve F, Andersen JT, Laustsen AH (2022)
    Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes
    Bioconjug Chem, 33 (8), 1494-1504
    DOI 10.1021/acs.bioconjchem.2c00220, PubMed 35875886
  12. Ward ES, Gelinas D, Dreesen E, Van Santbergen J, Andersen JT, Silvestri NJ, Kiss JE, Sleep D, Rader DJ, Kastelein JJP, Louagie E, Vidarsson G, Spriet I (2022)
    Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders
    Front Immunol, 13, 892534
    DOI 10.3389/fimmu.2022.892534, PubMed 35757719
  13. Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, Andersen JT, Haard H, Verheesen P, Bobkov V, Tikkanen R (2022)
    Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?
    Cells, 11 (6)
    DOI 10.3390/cells11060942, PubMed 35326398
  14. Zakrzewicz A, Würth C, Beckert B, Feldhoff S, Vanderheyden K, Foss S, Andersen JT, Haard H, Verheesen P, Bobkov V, Tikkanen R (2022)
    Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942
    Cells, 11 (10)
    DOI 10.3390/cells11101700, PubMed 35626757

Publications 2021

  1. Azevedo C, Andersen JT, Traverso G, Sarmento B (2021)
    The potential of porcine ex vivo platform for intestinal permeability screening of FcRn-targeted drugs
    Eur J Pharm Biopharm, 162, 99-104
    DOI 10.1016/j.ejpb.2021.03.009, PubMed 33771621
  2. Azevedo C, Pinto S, Benjakul S, Nilsen J, Santos HA, Traverso G, Andersen JT, Sarmento B (2021)
    Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery
    Adv Drug Deliv Rev, 175, 113778
    DOI 10.1016/j.addr.2021.04.016, PubMed 33887405
  3. Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
    Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
    Ann Intern Med, 174 (9), 1261-1269
    DOI 10.7326/M21-0653, PubMed 34251903
  4. Christopoulos PF, Gjølberg TT, Krüger S, Haraldsen G, Andersen JT, Sundlisæter E (2021)
    Targeting the Notch Signaling Pathway in Chronic Inflammatory Diseases
    Front Immunol, 12, 668207
    DOI 10.3389/fimmu.2021.668207, PubMed 33912195
  5. Høydahl LS, Frigstad T, Rasmussen IB, Øynebråten I, Schjetne KW, Andersen JT, Michaelsen TE, Lunde E, Bogen B, Sandlie I (2021)
    Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses
    Vaccine, 39 (11), 1583-1592
    DOI 10.1016/j.vaccine.2021.02.012, PubMed 33612340
  6. Jorstad OK, Sivertsen MS, Andersen JT, Moe MC (2021)
    Can the ampoules of covid-19 vaccine be used better?
    Tidsskr. Nor. Laegeforen., 141 (2), 110
  7. König M, Lorentzen ÅR, Torgauten HM, Tran TT, Schikora-Rustad S, Vaage EB, Mygland Å, Wergeland S, Aarseth J, Aaberge IAS, Torkildsen Ø, Holmøy T, Berge T, Myhr KM, Harbo HF, Andersen JT, Munthe LA, Søraas A, Celius EG, Vaage JT, Lund-Johansen F, Nygaard GO (2021)
    Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
    J Neurol Neurosurg Psychiatry, 94 (1), 19-22
    DOI 10.1136/jnnp-2021-327612, PubMed 34670844
  8. Mandrup OA, Ong SC, Lykkemark S, Dinesen A, Rudnik-Jansen I, Dagnæs-Hansen NF, Andersen JT, Alvarez-Vallina L, Howard KA (2021)
    Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
    Commun Biol, 4 (1), 310
    DOI 10.1038/s42003-021-01790-2, PubMed 33686177
  9. Merten H, Brandl F, Zimmermann M, Schaefer JV, Irpinio L, Sand KMK, Nilsen J, Andersen JT, Zangemeister-Wittke U, Plückthun A (2021)
    Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling
    Eur J Pharm Biopharm, 167, 104-113
    DOI 10.1016/j.ejpb.2021.07.011, PubMed 34303832
  10. Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
    Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
    MAbs, 13 (1), 1893888
    DOI 10.1080/19420862.2021.1893888, PubMed 33691596
  11. Sivertsen MS, Lode HE, Gjølberg TT, Petrovski G, Andersen JT, Jørstad ØK, Moe MC (2021)
    Cluster of symptomatic silicone oil droplets following intravitreal injections: a 1-year observational study
    BMJ Open Ophthalmol, 6 (1), e000764
    DOI 10.1136/bmjophth-2021-000764, PubMed 34485702
  12. Tunheim G, Rø GØI, Tran T, Kran AB, Andersen JT, Vaage EB, Kolderup A, Vaage JT, Lund-Johansen F, Hungnes O (2021)
    Trends in seroprevalence of SARS-CoV-2 and infection fatality rate in the Norwegian population through the first year of the COVID-19 pandemic
    Influenza Other Respir Viruses, 16 (2), 204-212
    DOI 10.1111/irv.12932, PubMed 34751488
  13. Aaen KH, Anthi AK, Sandlie I, Nilsen J, Mester S, Andersen JT (2021)
    The neonatal Fc receptor in mucosal immune regulation
    Scand J Immunol, 93 (2), e13017
    DOI 10.1111/sji.13017, PubMed 33351196

Publications 2020

  1. Azevedo C, Nilsen J, Grevys A, Nunes R, Andersen JT, Sarmento B (2020)
    Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin
    J Control Release, 327, 161-173
    DOI 10.1016/j.jconrel.2020.08.005, PubMed 32771477
  2. Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT (2020)
    An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
    Sci Transl Med, 12 (565)
    DOI 10.1126/scitranslmed.abb0580, PubMed 33055243
  3. Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, O'Connell K, Mayes K, Higginson K, Iturriza-Gómara M, Desselberger U, James LC (2020)
    Intracellular neutralisation of rotavirus by VP6-specific IgG
    PLoS Pathog, 16 (8), e1008732
    DOI 10.1371/journal.ppat.1008732, PubMed 32750093
  4. Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
    Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
    Proc Natl Acad Sci U S A, 117 (40), 25018-25025
    DOI 10.1073/pnas.2010540117, PubMed 32943538
  5. Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, Grevys A, Foss S, Menzies SC, Glickman JN, Fiebiger E, Roopenian DC, Sandlie I, Andersen JT, Sly LM, Baker K, Blumberg RS (2020)
    FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity
    J Exp Med, 217 (10)
    DOI 10.1084/jem.20200359, PubMed 32658257
  6. Jørstad ØK, Sivertsen MS, Andersen JT, Moe MC (2020)
    [Can vials of COVID-19 vaccine be used more effectively?]
    Tidsskr Nor Laegeforen, 140 (2)
    DOI 10.4045/tidsskr.20.1039, PubMed 33528143
  7. Lau C, McAdam MB, Bergseth G, Grevys A, Bruun JA, Ludviksen JK, Fure H, Espevik T, Moen A, Andersen JT, Mollnes TE (2020)
    NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies
    MAbs, 12 (1), 1686319
    DOI 10.1080/19420862.2019.1686319, PubMed 31671278
  8. Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, Roopenian DC, Sandlie I, Rand KD, Andersen JT (2020)
    An intact C-terminal end of albumin is required for its long half-life in humans
    Commun Biol, 3 (1), 181
    DOI 10.1038/s42003-020-0903-7, PubMed 32313072

Publications 2019

  1. Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Lode HE, McAdam MB, Sandlie I, Andersen JT, James LC (2019)
    Complement C4 Prevents Viral Infection through Capsid Inactivation
    Cell Host Microbe, 25 (4), 617-629.e7
    DOI 10.1016/j.chom.2019.02.016, PubMed 30926239
  2. Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT (2019)
    TRIM21-From Intracellular Immunity to Therapy
    Front Immunol, 10, 2049
    DOI 10.3389/fimmu.2019.02049, PubMed 31555278
  3. Labzin LI, Bottermann M, Rodriguez-Silvestre P, Foss S, Andersen JT, Vaysburd M, Clift D, James LC (2019)
    Antibody and DNA sensing pathways converge to activate the inflammasome during primary human macrophage infection
    EMBO J, 38 (21), e101365
    DOI 10.15252/embj.2018101365, PubMed 31468569
  4. Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT (2019)
    A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
    Sci Rep, 9 (1), 18021
    DOI 10.1038/s41598-019-54226-7, PubMed 31792234
  5. Maaland AF, Heyerdahl H, O'Shea A, Eiriksdottir B, Pascal V, Andersen JT, Kolstad A, Dahle J (2019)
    Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
    Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
    DOI 10.1007/s00259-019-04417-1, PubMed 31309259
  6. Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019)
    The Neonatal Fc Receptor (FcRn): A Misnomer?
    Front Immunol, 10, 1540
    DOI 10.3389/fimmu.2019.01540, PubMed 31354709
  7. Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
    Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
    Nat Nanotechnol, 14 (2), 184-190
    DOI 10.1038/s41565-018-0336-3, PubMed 30643273
  8. Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
    Publisher Correction: Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
    Nat Nanotechnol, 14 (4), 398
    DOI 10.1038/s41565-019-0404-3, PubMed 30783200

Publications 2018

  1. Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Hirst JC, McAdam MB, Slodkowicz G, Hutchinson E, Kozik P, Andersen JT, James LC (2018)
    TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination
    Proc Natl Acad Sci U S A, 115 (41), 10440-10445
    DOI 10.1073/pnas.1806314115, PubMed 30209217
  2. Grevys A, Nilsen J, Sand KMK, Daba MB, Øynebråten I, Bern M, McAdam MB, Foss S, Schlothauer T, Michaelsen TE, Christianson GJ, Roopenian DC, Blumberg RS, Sandlie I, Andersen JT (2018)
    A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
    Nat Commun, 9 (1), 621
    DOI 10.1038/s41467-018-03061-x, PubMed 29434196
  3. Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT (2018)
    Human and mouse albumin bind their respective neonatal Fc receptors differently
    Sci Rep, 8 (1), 14648
    DOI 10.1038/s41598-018-32817-0, PubMed 30279529
  4. Nilsen J, Sandlie I, Roopenian DC, Andersen JT (2018)
    Animal models for evaluation of albumin-based therapeutics
    Curr. Opin. Chem. Eng., 19, 68-76
    DOI 10.1016/j.coche.2017.11.007
  5. Sivertsen MS, Jørstad ØK, Grevys A, Foss S, Moe MC, Andersen JT (2018)
    Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
    Sci Rep, 8 (1), 2101
    DOI 10.1038/s41598-018-20525-8, PubMed 29391560
  6. Stapleton NM, Armstrong-Fisher SS, Andersen JT, van der Schoot CE, Porter C, Page KR, Falconer D, de Haas M, Williamson LM, Clark MR, Vidarsson G, Armour KL (2018)
    Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport
    Mol Immunol, 95, 1-9
    DOI 10.1016/j.molimm.2018.01.006, PubMed 29367080

Publications 2017

  1. Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2017)
    Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity
    Sci Rep, 7, 45418
    DOI 10.1038/srep45418, PubMed 28382939
  2. Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, Taylor ZS, McDonnell K, Nienaber V, Andersen JT, Mizoguchi A, Blumberg L, Purohit S, Jones SD, Christianson G, Lencer WI, Sandlie I, Kaplowitz N, Roopenian DC, Blumberg RS (2017)
    Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury
    Proc Natl Acad Sci U S A, 114 (14), E2862-E2871
    DOI 10.1073/pnas.1618291114, PubMed 28330995

Publications 2016

  1. Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2016)
    Antibody-antigen kinetics constrain intracellular humoral immunity
    Sci Rep, 6, 37457
    DOI 10.1038/srep37457, PubMed 27881870
  2. Cardoso I, Østerlund EC, Stamnaes J, Iversen R, Andersen JT, Jørgensen TJ, Sollid LM (2016)
    Dissecting the interaction between transglutaminase 2 and fibronectin
    Amino Acids, 49 (3), 489-500
    DOI 10.1007/s00726-016-2296-y, PubMed 27394141
  3. Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Høydahl LS, Dalhus B, Michaelsen TE, Sandlie I, James LC, Andersen JT (2016)
    TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity
    J Immunol, 196 (8), 3452-3459
    DOI 10.4049/jimmunol.1502601, PubMed 26962230

Publications 2015

  1. Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT (2015)
    The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
    J Control Release, 211, 144-62
    DOI 10.1016/j.jconrel.2015.06.006, PubMed 26055641
  2. Cardoso I, Stamnaes J, Andersen JT, Melino G, Iversen R, Sollid LM (2015)
    Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies
    FEBS J, 282 (11), 2063-75
    DOI 10.1111/febs.13276, PubMed 25808416
  3. Chen X, Hnida K, Graewert MA, Andersen JT, Iversen R, Tuukkanen A, Svergun D, Sollid LM (2015)
    Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease
    J Biol Chem, 290 (35), 21365-75
    DOI 10.1074/jbc.M115.669895, PubMed 26160175
  4. Czajkowsky DM, Andersen JT, Fuchs A, Wilson TJ, Mekhaiel D, Colonna M, He J, Shao Z, Mitchell DA, Wu G, Dell A, Haslam S, Lloyd KA, Moore SC, Sandlie I, Blundell PA, Pleass RJ (2015)
    Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications
    Sci Rep, 5, 9526
    DOI 10.1038/srep09526, PubMed 25912958
  5. Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT (2015)
    Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
    J Control Release, 223, 42-52
    DOI 10.1016/j.jconrel.2015.12.033, PubMed 26718855
  6. Foss S, Watkinson R, Sandlie I, James LC, Andersen JT (2015)
    TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity
    Immunol Rev, 268 (1), 328-39
    DOI 10.1111/imr.12363, PubMed 26497531
  7. Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT (2015)
    Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
    J Immunol, 194 (11), 5497-508
    DOI 10.4049/jimmunol.1401218, PubMed 25904551
  8. Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2015)
    Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
    Front Immunol, 5, 682
    DOI 10.3389/fimmu.2014.00682, PubMed 25674083

Publications 2014

  1. Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J (2014)
    Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding
    J Biol Chem, 289 (19), 13492-502
    DOI 10.1074/jbc.M114.549832, PubMed 24652290
  2. Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispens T, van der Schoot CE, Vidarsson G (2014)
    On the perplexingly low rate of transport of IgG2 across the human placenta
    PLoS One, 9 (9), e108319
    DOI 10.1371/journal.pone.0108319, PubMed 25251461
  3. Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, Christiansen D, Lau C, Brekke OL, Armstrong E, Stefanovic V, Andersen JT, Sandlie I, Mollnes TE (2014)
    Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
    Immunobiology, 220 (4), 452-9
    DOI 10.1016/j.imbio.2014.11.003, PubMed 25468724
  4. Rahman MA, Kristiansen PE, Veiseth SV, Andersen JT, Yap KL, Zhou MM, Sandlie I, Thorstensen T, Aalen RB (2014)
    The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure
    Biochemistry, 53 (13), 2091-100
    DOI 10.1021/bi401436h, PubMed 24625295
  5. Sand KM, Bern M, Nilsen J, Dalhus B, Gunnarsen KS, Cameron J, Grevys A, Bunting K, Sandlie I, Andersen JT (2014)
    Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn)
    J Biol Chem, 289 (50), 34583-94
    DOI 10.1074/jbc.M114.587675, PubMed 25344603
  6. Sand KM, Dalhus B, Christianson GJ, Bern M, Foss S, Cameron J, Sleep D, Bjørås M, Roopenian DC, Sandlie I, Andersen JT (2014)
    Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies
    J Biol Chem, 289 (24), 17228-39
    DOI 10.1074/jbc.M113.522565, PubMed 24764301

Publications 2013

  1. Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I (2013)
    Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics
    J Biol Chem, 288 (33), 24277-85
    DOI 10.1074/jbc.M113.463000, PubMed 23818524
  2. Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I (2013)
    Selection of nanobodies that target human neonatal Fc receptor
    Sci Rep, 3, 1118
    DOI 10.1038/srep01118, PubMed 23346375
  3. Jacobsen JT, Sundvold-Gjerstad V, Skjeldal FM, Andersen JT, Abrahamsen G, Bakke O, Spurkland A, Bogen B (2013)
    B-cell tolerance to the B-cell receptor variable regions
    Eur J Immunol, 43 (10), 2577-87
    DOI 10.1002/eji.201243203, PubMed 23839948
  4. Lau C, Gunnarsen KS, Høydahl LS, Andersen JT, Berntzen G, Pharo A, Lindstad JK, Ludviksen JK, Brekke OL, Barratt-Due A, Nielsen EW, Stokes CR, Espevik T, Sandlie I, Mollnes TE (2013)
    Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation
    J Immunol, 191 (9), 4769-77
    DOI 10.4049/jimmunol.1301653, PubMed 24062486
  5. Mathiesen L, Nielsen LK, Andersen JT, Grevys A, Sandlie I, Michaelsen TE, Hedegaard M, Knudsen LE, Dziegiel MH (2013)
    Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions
    Blood, 122 (7), 1174-81
    DOI 10.1182/blood-2012-12-473843, PubMed 23843496

Publications 2012

  1. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjørås M, Sleep D, Sandlie I (2012)
    Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
    Nat Commun, 3, 610
    DOI 10.1038/ncomms1607, PubMed 22215085
  2. Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I (2012)
    Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life
    J Biol Chem, 287 (27), 22927-37
    DOI 10.1074/jbc.M112.355131, PubMed 22570488
  3. Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, Sarkar CA, Georgiou G (2012)
    Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity
    ACS Chem Biol, 8 (2), 368-75
    DOI 10.1021/cb300455f, PubMed 23030766
  4. Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, Orcutt KD, Wittrup KD, Shively JE, Raubitschek A, Colcher D (2012)
    A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
    Protein Eng Des Sel, 26 (3), 187-93
    DOI 10.1093/protein/gzs096, PubMed 23175797

Publications 2011

  1. Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, Sandlie I, Chen Z, de Haar C, Lencer WI, Fiebiger E, Blumberg RS (2011)
    Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
    Proc Natl Acad Sci U S A, 108 (24), 9927-32
    DOI 10.1073/pnas.1019037108, PubMed 21628593
  2. Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, McIntosh RS, Sandlie I, He J, Hu J, Shao Z, Pleass RJ (2011)
    Polymeric human Fc-fusion proteins with modified effector functions
    Sci Rep, 1, 124
    DOI 10.1038/srep00124, PubMed 22355641
  3. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G (2011)
    Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
    Nat Commun, 2, 599
    DOI 10.1038/ncomms1608, PubMed 22186895

Publications 2010

  1. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C (2010)
    Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
    J Biol Chem, 286 (7), 5234-41
    DOI 10.1074/jbc.M110.164848, PubMed 21138843

Publications 2009

  1. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I (2009)
    Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding
    J Biol Chem, 285 (7), 4826-36
    DOI 10.1074/jbc.M109.081828, PubMed 20018855
  2. Andersen JT, Daba MB, Sandlie I (2009)
    FcRn binding properties of an abnormal truncated analbuminemic albumin variant
    Clin Biochem, 43 (4-5), 367-72
    DOI 10.1016/j.clinbiochem.2009.12.001, PubMed 20006594
  3. Andersen JT, Sandlie I (2009)
    The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics
    Drug Metab Pharmacokinet, 24 (4), 318-32
    DOI 10.2133/dmpk.24.318, PubMed 19745559

Publications 2008

  1. Berntzen G, Andersen JT, Ustgård K, Michaelsen TE, Mousavi SA, Qian JD, Kristiansen PE, Lauvrak V, Sandlie I (2008)
    Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation
    J Biol Chem, 284 (2), 1126-35
    DOI 10.1074/jbc.M803584200, PubMed 18957413
  2. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS (2008)
    Dependence of antibody-mediated presentation of antigen on FcRn
    Proc Natl Acad Sci U S A, 105 (27), 9337-42
    DOI 10.1073/pnas.0801717105, PubMed 18599440

Publications 2007

  1. Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I (2007)
    A strategy for bacterial production of a soluble functional human neonatal Fc receptor
    J Immunol Methods, 331 (1-2), 39-49
    DOI 10.1016/j.jim.2007.11.003, PubMed 18155020
  2. Andersen JT, Sandlie I (2007)
    A receptor-mediated mechanism to support clinical observation of altered albumin variants
    Clin Chem, 53 (12), 2216
    DOI 10.1373/clinchem.2007.097071, PubMed 18267931

Publications 2006

  1. Andersen JT, Dee Qian J, Sandlie I (2006)
    The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin
    Eur J Immunol, 36 (11), 3044-51
    DOI 10.1002/eji.200636556, PubMed 17048273

Publications 2005

  1. Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I (2005)
    Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells
    J Immunol Methods, 298 (1-2), 93-104
    DOI 10.1016/j.jim.2005.01.002, PubMed 15847800

 
Scroll to top